Assessing Tumor-Infiltrating Lymphocytes in Breast Cancer: A Proposal for Combining Immunohistochemistry and Gene Expression Analysis to Refine Scoring

Scoring of tumor-infiltrating lymphocytes (TILs) in breast cancer specimens has gained increasing attention, as TILs have prognostic and predictive value in HER2+ and triple-negative breast cancer. We evaluated the intra- and interrater variability when scoring TILs by visual inspection of hematoxylin and eosin-stained tissue sections. We further addressed whether immunohistochemical staining of these sections for immune cell surface markers CD45, CD3, CD4, and CD8 and combination with nanoString nCounter® gene expression analysis could refine TIL scoring. Formalin-fixed paraffin-embedded and fresh-frozen core needle biopsies of 12 female and treatment-naive breast cancer patients were included. Scoring of TILs was performed twice by three independent pathologists with a washout period of 3 days. Increasing intra- and interrater variability was observed with higher TIL numbers. The highest reproducibility was observed on tissue sections stained for CD3 and CD8. The latter TIL scores correlated well with the TIL scores obtained through nanoString nCounter® gene expression analysis. Gene expression analysis also revealed 104 and 62 genes that are positively and negatively related to both TIL scores. In conclusion, integration of immunohistochemistry and gene expression analysis is a valuable strategy to refine TIL scoring in breast tumors.

[1]  D. Larsimont,et al.  Functional Th1-oriented T follicular helper cells that infiltrate human breast cancer promote effective adaptive immunity. , 2021, The Journal of clinical investigation.

[2]  K. Thielemans,et al.  Overcoming the Challenges of High Quality RNA Extraction from Core Needle Biopsy , 2021, Biomolecules.

[3]  X. Zhang,et al.  Tumor-Associated Neutrophils and Macrophages—Heterogenous but Not Chaotic , 2020, Frontiers in Immunology.

[4]  I. Barshack,et al.  Fibroblast-Derived IL33 Facilitates Breast Cancer Metastasis by Modifying the Immune Microenvironment and Driving Type 2 Immunity , 2020, Cancer Research.

[5]  Yuhan Zhang,et al.  Loco-regional recurrence trend and prognosis in young women with breast cancer according to molecular subtypes: analysis of 1099 cases , 2020, World Journal of Surgical Oncology.

[6]  A. Belfiore,et al.  The IL1β-IL1R signaling is involved in the stimulatory effects triggered by hypoxia in breast cancer cells and cancer-associated fibroblasts (CAFs) , 2020, Journal of experimental & clinical cancer research : CR.

[7]  C. Ni,et al.  A Rosetta Stone for Breast Cancer: Prognostic Value and Dynamic Regulation of Neutrophil in Tumor Microenvironment , 2020, Frontiers in Immunology.

[8]  J. Galon,et al.  The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy , 2020, Nature Reviews Cancer.

[9]  Michael D. Brooks,et al.  Increased Expression of Interleukin-1 Receptor Characterizes Anti-estrogen-Resistant ALDH+ Breast Cancer Stem Cells , 2020, Stem cell reports.

[10]  J. Koo,et al.  Clinicopathologic Characteristics of Breast Cancer According to the Infiltrating Immune Cell Subtypes , 2020, International journal of molecular sciences.

[11]  Andrew H. Beck,et al.  Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer , 2020, npj Breast Cancer.

[12]  G. Sandusky,et al.  ST2 as checkpoint target for colorectal cancer immunotherapy. , 2020, JCI insight.

[13]  A. Sapino,et al.  The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas , 2020, Pathobiology.

[14]  H. Wildiers,et al.  Computerised scoring protocol for identification and quantification of different immune cell populations in breast tumour regions by the use of QuPath software , 2020, Histopathology.

[15]  Arjun Bhattacharya,et al.  An approach for normalization and quality control for NanoString RNA expression data , 2020, bioRxiv.

[16]  Xikun Zhou,et al.  Tumor-Associated Macrophages: Recent Insights and Therapies , 2020, Frontiers in Oncology.

[17]  Sung-Bae Kim,et al.  Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Yuan Wang,et al.  Single-Cell Map of Diverse Immune Phenotypes in the Metastatic Brain Tumor Microenvironment of Non Small Cell Lung Cancer , 2019, bioRxiv.

[19]  Tonje G. Lien,et al.  An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment , 2019, Nature Communications.

[20]  E. Winer,et al.  Estimating the Benefits of Therapy for Early Stage Breast Cancer The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  H. Putter,et al.  The intra-tumoural stroma in patients with breast cancer increases with age , 2019, Breast Cancer Research and Treatment.

[22]  J. Kos,et al.  Cysteine Cathepsins in Tumor-Associated Immune Cells , 2019, Front. Immunol..

[23]  D. McArt,et al.  A Novel Role for Cathepsin S as a Potential Biomarker in Triple Negative Breast Cancer , 2019, Journal of oncology.

[24]  C. Mazzanti,et al.  Molecular profiling of microinvasive breast cancer microenvironment progression , 2019, Journal of Translational Medicine.

[25]  K. Ley,et al.  Macrophage Polarization: Different Gene Signatures in M1(LPS+) vs. Classically and M2(LPS–) vs. Alternatively Activated Macrophages , 2019, Front. Immunol..

[26]  M. Kurosumi,et al.  Prognostic significance of tumour-infiltrating lymphocytes for oestrogen receptor-negative breast cancer without lymph node metastasis , 2019, Oncology letters.

[27]  Heikki Joensuu,et al.  Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Xining Li,et al.  Comprehensive analysis of coexpressed long noncoding RNAs and genes in breast cancer , 2018, The journal of obstetrics and gynaecology research.

[29]  C. Dinarello.  An Interleukin-1 Signature in Breast Cancer Treated with Interleukin-1 Receptor Blockade: Implications for Treating Cytokine Release Syndrome of Checkpoint Inhibitors. , 2018, Cancer research.

[30]  T. Mukohara,et al.  Adipose-derived stem cells enhance human breast cancer growth and cancer stem cell-like properties through adipsin , 2018, Oncogene.

[31]  Y. De Vlaeminck,et al.  Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression , 2018, Front. Immunol..

[32]  Ambrose J. Carr,et al.  Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment , 2018, Cell.

[33]  P. Heikkilä,et al.  Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study , 2018, Breast Cancer Research and Treatment.

[34]  S. McArdle,et al.  Immune Landscape of Breast Cancers , 2018, Biomedicines.

[35]  A. Shaw,et al.  Tumour heterogeneity and resistance to cancer therapies , 2018, Nature Reviews Clinical Oncology.

[36]  T. Tramm,et al.  Standardized assessment of tumor-infiltrating lymphocytes in breast cancer: an evaluation of inter-observer agreement between pathologists , 2018, Acta oncologica.

[37]  Pankaj K. Choudhary,et al.  Measuring Agreement: Models, Methods, and Applications , 2017 .

[38]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[39]  K. Ley,et al.  Natural variation of macrophage activation as disease-relevant phenotype predictive of inflammation and cancer survival , 2017, Nature Communications.

[40]  C. Sotiriou,et al.  Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer , 2017, Modern Pathology.

[41]  L. Pilarski,et al.  MS4A4A: a novel cell surface marker for M2 macrophages and plasma cells , 2017, Immunology and cell biology.

[42]  J. Ravetch,et al.  The Role and Function of Fcγ Receptors on Myeloid Cells , 2016, Microbiology spectrum.

[43]  Carsten Denkert,et al.  Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group , 2016, Modern Pathology.

[44]  Patrick Danaher,et al.  Gene expression markers of Tumor Infiltrating Leukocytes , 2016, Journal of Immunotherapy for Cancer.

[45]  D. Coppola,et al.  Therapeutic targeting of myeloid-derived suppressor cells involves a novel mechanism mediated by clusterin , 2016, Scientific Reports.

[46]  Carsten Denkert,et al.  Clinical relevance of host immunity in breast cancer: from TILs to the clinic , 2016, Nature Reviews Clinical Oncology.

[47]  M. Mathieu,et al.  Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  Carsten Denkert,et al.  Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[50]  Molin Wang,et al.  Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  S. Dudoit,et al.  Normalization of RNA-seq data using factor analysis of control genes or samples , 2014, Nature Biotechnology.

[52]  S Michiels,et al.  Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  I. Park,et al.  Clusterin stimulates the chemotactic migration of macrophages through a pertussis toxin sensitive G-protein-coupled receptor and Gβγ-dependent pathways. , 2014, Biochemical and biophysical research communications.

[54]  Carsten Denkert,et al.  Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial , 2013, PloS one.

[55]  Stefan Michiels,et al.  Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[57]  Bendix Carstensen,et al.  Comparing Clinical Measurement Methods: A Practical Guide , 2010 .

[58]  F. Pépin,et al.  Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.

[59]  R. Gray,et al.  Tumor-In fi ltrating Lymphocytes and Prognosis : A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers , 2019 .

[60]  P. Fasching,et al.  Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. , 2018, The Lancet. Oncology.

[61]  L. Pilarski,et al.  MS 4 A 4 A : a novel cell surface marker for M 2 macrophages and plasma cells Running Title : MS 4 A 4 A expression in hematopoietic cells , 2017 .

[62]  J. Sun,et al.  Regulatory T cells are an important prognostic factor in breast cancer: a systematic review and meta-analysis. , 2016, Neoplasma.